Synergen Pharma India Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
as on 14-12-2024
- Paid Up Capital ₹ 1.49 Cr
as on 14-12-2024
- Company Age 9 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 24.15%
(FY 2022)
- Profit 49.76%
(FY 2022)
- Ebitda 204.12%
(FY 2022)
- Net Worth -6.96%
(FY 2022)
- Total Assets 11.57%
(FY 2022)
About Synergen Pharma India
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 1.49 Cr, as per Ministry of Corporate Affairs (MCA) records.
Sankaraviswanathan Kalyanasundaram, Senthil Balasubramanian, and Sankara Hariharan serve as directors at the Company.
- CIN/LLPIN
U24100TN2015PTC101824
- Company No.
101824
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 Aug 2015
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Synergen Pharma India Private Limited offer?
Synergen Pharma India Private Limited offers a wide range of products and services, including Nutraceuticals & Dietary Supplements, Nutraceuticals.
Who are the key members and board of directors at Synergen Pharma India?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sankaraviswanathan Kalyanasundaram  | Director | 13-Aug-2015 | Current |
| Senthil Balasubramanian | Director | 11-Mar-2016 | Current |
| Sankara Hariharan | Director | 23-Nov-2017 | Current |
Financial Performance of Synergen Pharma India.
Synergen Pharma India Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 24.15% increase. The company also saw a substantial improvement in profitability, with a 49.76% increase in profit. The company's net worth dipped by a decrease of 6.96%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Synergen Pharma India?
In 2020, Synergen Pharma India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Visaka Business Solutions (Opc) Private LimitedActive 4 years 11 monthsSankaraviswanathan Kalyanasundaram is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Synergen Pharma India?
Synergen Pharma India has a workforce of 9 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Synergen Pharma India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Synergen Pharma India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
